Kopetz, S., Yoshino, T., Kim, T. W., Desai, J., Yaeger, R., Van Cutsem, E., . . . Tabernero, J. (1/6/2022 Supplement). BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF V600E) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 40, 134-135.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Kopetz, Scott, et al. "BREAKWATER Safety Lead-in (SLI): Encorafenib + Cetuximab (EC) ± Chemotherapy for First-line (1L) Treatment (tx) of BRAF V600E-mutant (BRAF V600E) Metastatic Colorectal Cancer (mCRC)."
Journal of Clinical Oncology 40 (1/6/2022 Supplement): 134-135.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Kopetz, Scott, et al. "BREAKWATER Safety Lead-in (SLI): Encorafenib + Cetuximab (EC) ± Chemotherapy for First-line (1L) Treatment (tx) of BRAF V600E-mutant (BRAF V600E) Metastatic Colorectal Cancer (mCRC)."
Journal of Clinical Oncology, vol. 40, 1/6/2022 Supplement, pp. 134-135.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.